Cell and gene therapy is past the ad hoc era of using what has always been available. Researchers have a choice in what manufacturing technologies are best for their process, and partners with early adoption programs can help therapy developers mitigate the risk of trying something new while maximizing the reward for being first in line. In this session, enjoy lunch and hear a distinguished group of leaders discuss their experience as early adopters of new technologies and the roles these partnerships played in optimization success. 

Agenda

12:30pm Panel

1:10pm Q&A

Speakers: 

Nisha C. Durand, PhD, Principal Research Technologist, Mayo Clinic

Matthew M. Hewitt, B.A. Ph.D, Executive Director, Scientific Services Cell and Gene Therapy, Charles River

Stuart Gibb, PhD, Scientific Strategy Lead, Terumo Blood and Cell Technologies